Business
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors REDWOOD CITY, Calif., March 11,
About this update from Revolution Medicines, Inc.
[{"type":"text","content":"Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors\nREDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced the company will make six presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held April 10-15, 2021 in a virtual format. Details of the planned presentations are as follows: Oral Presentation: Title: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers Abstract Number: LB001Session: Late-Breaking Minisymposium 1Date/Time: April 10, 2021 at 2:05 p.m. Eastern Poster Presentations: Title: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancersAbstract Number: 1260Session: Novel Antitumor AgentsDate/Time: April 10, 2021 at 8:30 a.m. Eastern Title: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibitionAbstract Number: 1261Session: Novel Antitumor AgentsDate/Time: April 10, 2021 at 8:30 a.m. Eastern Title: Discovery of a potent, selective, and orally bioavailable SOS1 inhibitor, RMC-023, an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction Abstract Number: 1273Session: Novel Antitumor AgentsDate/Time: April 10, 2021 at 8:30 a.m. Eastern Title: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630Abstract Number: LB050Session:Immune Response to TherapiesDate: April 10, 2021 at 8:30 a.m. Eastern Title: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical studyAbstract Number: LB054Session: Liquid Biopsies: Circulating DNADate: April 10, 2021 at 8:30 a.m. Eastern Additional information on the AACR Annual Meeting 2021 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meet...